Faster access for rare disease patients starts with smarter alignment

0 min

Published on: Jun 22, 2026

Rare disease innovation is advancing faster than ever — with breakthroughs in genomics, AI-enabled diagnostics, and innovative trial designs transforming what’s possible. Yet without global alignment, progress stalls. Sponsors still face fragmented regulatory expectations, inconsistent real-world data standards, limited natural history data, and trial designs accepted in one region but rejected in another. The result is duplicated effort, slower development, and ultimately, delayed access to life-changing therapies for the patients who need them most. 

Watch our panel at this year’s World Orphan Drug Conference to hear the importance of global regulatory alignment, innovative trial designs, real-world data standards, and sustained momentum in the rare disease community to accelerate patient access to therapies.

Return to Insights Center

Related Insights


Back

Access exclusive insights

Harness the power of clinical development with exclusive insights from our experts at Parexel

Would you like to hear from us in the future?

Stay connected with Parexel!

Accept

Decline